Galapagos NV (GLPG)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Galapagos NV (“Galapagos” or the "Company") (NASDAQ: GLPG). The investigation concerns whether Galapagos and certain of its officers and/or directors have violated federal securities laws.
On February 10, 2021, Galapagos and its development partner Gilead Sciences (“Gilead”) issued a press release “announc[ing] the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis.” Galapagos and Gilead stated that “[t]he decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies.” On this news, Galapagos’s stock price fell $19.41 per share, or 17.76%, to close at $89.90 per share on February 10, 2021.
If you are aware of any facts relating to this investigation, or purchased Galapagos shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.